TherapeuticsMD (TXMD) Common Equity (2010 - 2026)

TherapeuticsMD's Common Equity history runs 17 years deep, the most recent figure standing at $27.0 million for Q1 2026.

• Quarterly Common Equity rose 0.87% year-over-year to $27.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.0 million (up 0.87% YoY) and the FY2025 annual result came in at $26.9 million, down 1.8% from the prior year.
• Common Equity was $27.0 million for Q1 2026 at TherapeuticsMD, roughly flat from $26.9 million in the prior quarter.
• Across five years, Common Equity topped out at $35.1 million in Q4 2022 and bottomed at -$140.6 million in Q1 2022.
• A 5-year average of $11.0 million and a median of $27.4 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity slumped 1383.22% — and 2023, when it soared 219.68%.
• TherapeuticsMD's Common Equity stood at $35.1 million in 2022, then slipped by 16.66% to $29.3 million in 2023, then slipped by 6.55% to $27.4 million in 2024, then dropped by 1.8% to $26.9 million in 2025, then climbed by 0.36% to $27.0 million in 2026.
• Business Quant data shows TXMD's Common Equity at $27.0 million in Q1 2026, $26.9 million in Q4 2025, and $27.4 million in Q3 2025.